For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established. For infants born to mothers with clinically apparent gonorrh...
Dosage and administration
In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. T...
Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3-
C-methyl-3-
0-methyl-α-L-
ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-
xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione) is antibiotic produced from a strain of
Streptomyces erythraeus. It has the following structural formula:
Structure Image
Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.
CLINICAL PHARMACOLOGY:
CLINICAL PHARMACOLOGY SECTION
Microbiology:
MICROBIOLOGY SECTION
Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms
in vitroand in clinical infections:
Streptococcus pyogenes(group A ß-hemolytic)
Alpha-hemolytic streptococci (viridans group)
Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)
Streptococcus pneumonia
Mycoplasma pneumoniae(Eaton Agent, PPLO)
Haemophilus influenzae(not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)
Treponema pallidum
Corynebacterium diphtheriae
Neisseria gonorrhoeae
Chlamydia trachomatis
INDICATIONS AND USAGE:
INDICATIONS & USAGE SECTION
For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.
For prophylaxis of ophthalmia neonatorum due to
N. gonorrhoeaeor
C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing
N. gonorrheaeis not established.
For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.
CONTRAINDICATIONS:
CONTRAINDICATIONS SECTION
This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.
PRECAUTIONS:
PRECAUTIONS SECTION
General:
GENERAL PRECAUTIONS SECTION
The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.
Information for Patients:
INFORMATION FOR PATIENTS SECTION
Avoid contaminating the applicator tip with material from the eye, fingers, or other source.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION
Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted.
No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.
Pregnancy:
PREGNANCY SECTION
Teratogenic effects -
TERATOGENIC EFFECTS SECTION
Pregnancy Category B.
SPL UNCLASSIFIED SECTION
Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.
Nursing Mothers:
NURSING MOTHERS SECTION
Caution should be exercised when erythromycin is administered to a nursing woman.
Pediatric Use:
PEDIATRIC USE SECTION
See
INDICATIONS AND USAGEand
DOSAGE AND ADMINISTRATION.
ADVERSE REACTIONS:
ADVERSE REACTIONS SECTION
The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.
To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
DOSAGE AND ADMINISTRATION:
DOSAGE & ADMINISTRATION SECTION
In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.
HOW SUPPLIED
HOW SUPPLIED SECTION
Sterile Erythromycin Ophthalmic Ointment USP, 5 mg/g as follows:
3.5 g (1/8 oz) tamper-evident tubes NDC 0574-
4024-35
24 x 3.5 g (1/8 oz) Hospital-Pak (for hospital use only) NDC 0574-
4024-39
Carton of fifty (50) Unit Dose 1 g tubes NDC 0574-
4024-50
Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat.
Protect from freezing.
SPL UNCLASSIFIED SECTION
Manufactured For
Perrigo®
Minneapolis, MN 55427
SW700 RC J1 Rev 09-13 A
R1013
Ini 0813
Package/Label Display Panel - Label
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Rx Only
NDC 0574-
4024-35
Erythromycin Ophthalmic Ointment USP
NET WT 3.5 g (1/8 OZ)
STERILE
Erythromycin Ophthalmic Label.jpg
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
serialization-template.jpg
Package/Label Display Panel-Hospital - Pak
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
HOSPITAL-PAK
Rx Only
NDC 0574-
4024-39
Erythromycin Ophthalmic Ointment USP
STERILE – 5 mg per Gram
For Use in High Volume Neonatal Care
HOSPITAL USE ONLY
24 x 1/8 OZ (3.5 g)
Each gram contains 5 mg of Erythromycin USP in a sterile ophthalmic base of mineral oil and white petrolatum.
5w7-rc-erythromycin-ophthalmic-ointment-39.jpg
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
serialization-template.jpg
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - 50 Unit Doses
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.